Lucid Diagnostics Inc. (LUCD)Healthcare | Medical Devices | New York, United States | NasdaqCM
0.99 USD
+0.01
(0.752%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.00 +0.01 (0.867%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:15 a.m. EDT
The immediate outlook is neutral to slightly bearish due to a lack of clear directional momentum and a statistically weak short-term forecast, though the stock recently staged a recovery from multi-year lows. However, the long-term investment case is severely compromised by deteriorating fundamentals; the company is burning significant cash with negative operating margins and a massive debt-to-equity ratio, while the stock has lost more than half its value over the last three years despite a recent annual rebound. This divergence suggests the market is pricing in a high probability of failure or dilution rather than sustainable growth. Furthermore, there is no dividend income to offset these risks, making this a speculative vehicle unsuitable for capital preservation. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.052504 |
| AutoETS | 0.052504 |
| MSTL | 0.055536 |
| AutoTheta | 0.057795 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 5.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.999 |
| Excess Kurtosis | 0.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 227.958 |
| Revenue per Share | 0.039 |
| Market Cap | 189,306,576 |
| Forward P/E | -6.01 |
| Beta | 1.08 |
| Website | https://www.luciddx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22578126 |
| Address1 | 360 Madison Avenue |
| Address2 | 25th Floor |
| All Time High | 13.52 |
| All Time Low | 0.63 |
| Ask | 1.28 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 865,570 |
| Average Daily Volume3 Month | 1,395,790 |
| Average Volume | 1,395,790 |
| Average Volume10Days | 865,570 |
| Beta | 1.081 |
| Bid | 0.686 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 0.057 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.9914 |
| Current Ratio | 1.331 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.9981 |
| Day Low | 0.972 |
| Debt To Equity | 227.958 |
| Display Name | Lucid Diagnostics |
| Earnings Call Timestamp End | 1,786,624,200 |
| Earnings Call Timestamp Start | 1,786,624,200 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -49,808,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.609 |
| Enterprise To Revenue | 33.011 |
| Enterprise Value | 179,743,568 |
| Eps Current Year | -0.24333 |
| Eps Forward | -0.165 |
| Eps Trailing Twelve Months | -0.42 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.98964 |
| Fifty Day Average Change | 0.001760006 |
| Fifty Day Average Change Percent | 0.0017784305 |
| Fifty Two Week Change Percent | -22.578127 |
| Fifty Two Week High | 1.629 |
| Fifty Two Week High Change | -0.63759995 |
| Fifty Two Week High Change Percent | -0.39140576 |
| Fifty Two Week Low | 0.861 |
| Fifty Two Week Low Change | 0.1304 |
| Fifty Two Week Low Change Percent | 0.1514518 |
| Fifty Two Week Range | 0.861 - 1.629 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,634,218,200,000 |
| Float Shares | 140,761,675 |
| Forward Eps | -0.165 |
| Forward P E | -6.008485 |
| Free Cashflow | -26,429,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 82 |
| Fullday Change | 0.00739998 |
| Fullday Change Percent | 0.75203 |
| Fullday Price | 1.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -0.2169 |
| Gross Profits | -1,181,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.26504 |
| Held Percent Institutions | 0.33366 |
| Implied Shares Outstanding | 190,948,730 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-10-14 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc. |
| Long Name | Lucid Diagnostics Inc. |
| Market | us_market |
| Market Cap | 189,306,576 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_604709203 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -65,006,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 187,893,550 |
| Number Of Analyst Opinions | 5 |
| Open | 0.985 |
| Operating Cashflow | -46,869,000 |
| Operating Margins | -8.68453 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 917 813 1828 |
| Post Market Change | 0.008599997 |
| Post Market Change Percent | 0.86745983 |
| Post Market Price | 1.0 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 0.984 |
| Price Eps Current Year | -4.074302 |
| Price Hint | 4 |
| Price To Book | 17.392982 |
| Price To Sales Trailing12 Months | 34.767048 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.292 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | 0.00739998 |
| Regular Market Change Percent | 0.75203 |
| Regular Market Day High | 0.9999 |
| Regular Market Day Low | 0.972 |
| Regular Market Day Range | 0.972 - 0.9999 |
| Regular Market Open | 0.985 |
| Regular Market Previous Close | 0.984 |
| Regular Market Price | 0.9914 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 423,292 |
| Return On Assets | -0.81625 |
| Return On Equity | -5.56272 |
| Revenue Growth | 0.267 |
| Revenue Per Share | 0.039 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 190,948,730 |
| Shares Percent Shares Out | 0.0672 |
| Shares Short | 12,830,666 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 10,895,223 |
| Short Name | Lucid Diagnostics Inc. |
| Short Percent Of Float | 0.0864 |
| Short Ratio | 8.98 |
| Source Interval | 15 |
| State | NY |
| Symbol | LUCD |
| Target High Price | 9.5 |
| Target Low Price | 2.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 3.0 |
| Total Cash | 34,472,000 |
| Total Cash Per Share | 0.181 |
| Total Debt | 24,909,000 |
| Total Revenue | 5,445,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.11646 |
| Two Hundred Day Average Change | -0.12505996 |
| Two Hundred Day Average Change Percent | -0.11201473 |
| Type Disp | Equity |
| Volume | 423,292 |
| Website | https://www.luciddx.com |
| Zip | 10,017 |